MARKET

CNAT

CNAT

Conatus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3300
+0.0049
+1.51%
After Hours: 0.3300 0 0.00% 17:22 10/11 EDT
OPEN
0.3370
PREV CLOSE
0.3251
HIGH
0.3417
LOW
0.3300
VOLUME
249.36K
TURNOVER
--
52 WEEK HIGH
5.89
52 WEEK LOW
0.2500
MARKET CAP
10.95M
P/E (TTM)
-0.7493
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CNAT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CNAT News

  • Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes
  • Zacks.2d ago
  • Penumbra Enrolls First Patient for Study on Coronary Vessels
  • Zacks.2d ago
  • Conatus Pharmaceuticals And Novartis Mutually Agree To Terminate Collaboration Agreement Dated December 19, 2016
  • Benzinga.10/04 20:13
  • Conatus Pharma Shares Resume Trade, Down 21.6%
  • Benzinga.09/24 20:35

More

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.89%

Hot Stocks

Name
Price
%Change

About CNAT

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
More

Webull offers Conatus Pharmaceuticals Inc (CNAT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.